Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mindset Pharma Inc (OP: MSSTF )

0.2574 +0.0131 (+5.36%)
Streaming Delayed Price Updated: 3:37 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,162
Open 0.2491
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2443
Today's Range 0.2491 - 0.2574
52wk Range 0.1626 - 0.4595
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection
Numerous biopharma companies are working on enhancing first-generation or “classical” psychedelics. They're tuning down the side effects, and protecting their findings along the way. 
Via Benzinga

Performance

YTD
+3.58%
+3.58%
1 Month
+22.57%
+22.57%
3 Month
+31.80%
+31.80%
6 Month
-9.11%
-9.11%
1 Year
-6.67%
-6.67%

More News

Read More
New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Via Benzinga
Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court
Via Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Via Benzinga
Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla
Via Benzinga
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Via Benzinga
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
Via Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Via Benzinga
These Two Psychedelics Companies Team Up In An Exclusive Sales Deal, Here Are The Details
Via Benzinga
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
From PharmAla Biotech
Via GlobeNewswire
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance
Via Benzinga
European Psychedelics Research Group Nabs $2M In Seed Funding As Clinical Research Picks Up Speed
Via Benzinga
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Via Benzinga
Next-Generation Psychedelics Shows Promise With Upcoming Clinical Trials
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
Via Benzinga
Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close?
Via Benzinga
Psychedelics Companies Explore & Protect Their Findings, This Firm Is Doing That In 16 Countries
Via Benzinga
Psychedelic Stock Gainers And Losers From September 7, 2022
Via Benzinga
Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
Via Benzinga
Small Pharma, Revive Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
This Company Just Created 3 Brand New Psychedelics—Without The Hallucinogenic Side Effects
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.